



## **Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents**

Downloaded from <http://aidsinfo.nih.gov/guidelines> on 4/7/2015

Visit the *AIDSinfo* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <http://aidsinfo.nih.gov/e-news>.

Downloaded from <http://aidsinfo.nih.gov/guidelines> on 4/7/2015

# Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents




Developed by the HHS Panel on Antiretroviral Guidelines for  
Adults and Adolescents – A Working Group of the  
Office of AIDS Research Advisory Council (OARAC)

## How to Cite the Adult and Adolescent Guidelines:

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at <http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Section accessed [insert date] [insert page number, table number, etc., if applicable]

It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the *AIDSinfo* website (<http://aidsinfo.nih.gov>).



Access *AIDSinfo*  
mobile site

Downloaded from <http://aidsinfo.nih.gov/guidelines> on 4/7/2014

This interim revision of the Guidelines includes a revised section on Hepatitis C Virus (HCV)/HIV Coinfection, with emphasis on considerations for use of antiretroviral (ARV) drugs in patients who also receive treatment for HCV infection. A new table ([Table 12](#)) provides clinicians with guidance on the concomitant use of HCV drugs and ARV drugs, with a focus on potential pharmacokinetic drug interactions. The Panel refers clinicians to <http://www.hcvguidelines.org> for guidance on the diagnosis and treatment of HCV infections.

# Table of Contents

<b><i>What's New in the Guidelines</i></b> .....	i
<b><i>Panel Roster</i></b> .....	vi
<b><i>Financial Disclosure</i></b> .....	viii
<b><i>Introduction</i></b> .....	A-1
<i>Table 1. Outline of the Guidelines Development Process</i> .....	A-2
<i>Table 2. Rating Scheme for Recommendations</i> .....	A-3
<b><i>Baseline Evaluation</i></b> .....	B-1
<b><i>Laboratory Testing</i></b> .....	C-1
Laboratory Testing for Initial Assessment and Monitoring While on Antiretroviral Therapy .....	C-1
<i>Table 3. Laboratory Monitoring Schedule for Patients Before and After Initiation of Antiretroviral Therapy</i> .....	C-2
Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring .....	C-5
<i>Table 4. Recommendations on the Indications and Frequency of Viral Load and CD4 Count Monitoring</i> .....	C-8
Drug-Resistance Testing .....	C-11
<i>Table 5. Recommendations for Using Drug-Resistance Assays</i> .....	C-15
Co-Receptor Tropism Assays .....	C-20
HLA-B*5701 Screening .....	C-23
<b><i>Treatment Goals</i></b> .....	D-1
<b><i>Initiating Antiretroviral Therapy in Treatment-Naive Patients</i></b> .....	E-1
<b><i>What to Start</i></b> .....	F-1
<i>Table 6. Recommended and Alternative Antiretroviral Regimen Options for Treatment-Naive Patients</i> .....	F-7
<i>Table 7. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy</i> .....	F-22
<i>Table 8. Antiretroviral Components or Regimens Not Recommended as Initial Therapy</i> .....	F-25
<b><i>What Not to Use</i></b> .....	G-1
<i>Table 9. Antiretroviral Regimens or Components That Should Not Be Offered At Any Time</i> .....	G-3
<b><i>Management of the Treatment-Experienced Patient</i></b> .....	H-1
Virologic Failure and Suboptimal Immunologic Response .....	H-1
Regimen Switching in the Setting of Virologic Suppression .....	H-13
Exposure-Response Relationship and Therapeutic Drug Monitoring (TDM) for Antiretroviral Agents .....	H-17
<i>Table 10a. Trough Concentrations of Antiretroviral Drugs for Patients Who Have Drug-Susceptible Virus</i> .....	H-19

<i>Table 10b. Trough Concentrations of Antiretroviral Drugs for Treatment-Experienced Patients with Virologic Failure</i> .....	H-20
Discontinuation or Interruption of Antiretroviral Therapy .....	H-21
<b>Considerations for Antiretroviral Use in Special Patient Populations</b> .....	I-1
Acute and Recent (Early) HIV Infection .....	I-1
<i>Table 11. Identifying, Diagnosing, and Managing Acute and Recent HIV-1 Infection</i> .....	I-5
HIV-Infected Adolescents and Young Adults .....	I-8
HIV and Illicit Drug Users .....	I-14
HIV-Infected Women .....	I-18
HIV-2 Infection .....	I-25
HIV and the Older Patient .....	I-28
<b>Considerations for Antiretroviral Use in Patients with Coinfections</b> .....	J-1
Hepatitis B (HBV)/HIV Coinfection .....	J-1
Hepatitis C (HCV)/HIV Coinfection .....	J-5
<i>Table 12. Recommendations for Concomitant Use of Selected Antiretroviral Drugs and All Food and Drug Administration (FDA)-Approved Drugs for Treatment of Hepatitis C in HIV-Infected Adults</i> .....	J-9
<i>Mycobacterium Tuberculosis</i> Disease with HIV Coinfection .....	J-14
<b>Limitations to Treatment Safety and Efficacy</b> .....	K-1
Adherence to Antiretroviral Therapy .....	K-1
<i>Table 13. Strategies to Improve Adherence to Antiretroviral Therapy and Retention in Care</i> .....	K-4
Adverse Effects of Antiretroviral Agents .....	K-8
<i>Table 14. Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects</i> .....	K-9
<i>Table 15. Antiretroviral Therapy-Associated Adverse Events That Can Be Managed with Substitution of Alternative Antiretroviral Agent</i> .....	K-17
Cost Considerations and Antiretroviral Therapy .....	K-21
<i>Table 16. Monthly Average Wholesale Price of Antiretroviral Drugs</i> .....	K-22
<b>Drug Interactions</b> .....	L-1
<i>Table 17. Drugs That Should Not Be Used With Antiretroviral Agents</i> .....	L-4
<i>Table 18a. Drug Interactions between Protease Inhibitors and Other Drugs</i> .....	L-6
<i>Table 18b. Drug Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors and Other Drugs</i> .....	L-18
<i>Table 18c. Drug Interactions between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents)</i> .....	L-25
<i>Table 18d. Drug Interactions between Integrase Strand Transfer Inhibitors and Other Drugs</i> .....	L-27
<i>Table 18e. Drug Interactions between CCR5 Antagonist and Other Drugs</i> .....	L-35
<i>Table 19a. Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors</i> .....	L-37
<i>Table 19b. Interactions between Integrase Strand Transfer Inhibitors and</i>	

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.